Breaking News

Reaction Biology Selected for Specialized Center in Chemical Biology Consortium

Project includes developing a robust SPR assay to measure the binding affinity of small molecules to human target proteins.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Reaction Biology Corp., a provider of drug discovery services, has been selected to participate as a Specialized Center in the Chemical Biology Consortium (CBC), the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR), a federal national lab sponsored by the NCI, part of the National Institutes of Health, and currently operated by Leidos Biomedical Research, Inc.   T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters